Combination Medications vs. Patch Alone for Medically-Ill Smokers

This study has been completed.
Sponsor:
Collaborators:
Rutgers Cancer Institute of New Jersey
Robert Wood Johnson Foundation
Information provided by:
Rutgers, The State University of New Jersey
ClinicalTrials.gov Identifier:
NCT00770666
First received: October 9, 2008
Last updated: NA
Last verified: October 2008
History: No changes posted
  Purpose

Randomized clinical trial to evaluate a flexibly-dosed-3-medication combination for up to 6 months in smokers with medical illness


Condition Intervention Phase
Smoking Cessation
Drug: Nicotine patch, nicotine inhaler, bupropion
Drug: Nicotine patch
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Flexibly-Dosed Combination Pharmacotherapy Versus Standard-Dosed Nicotine Patch Alone for Smokers With Medical Illness

Resource links provided by NLM:


Further study details as provided by Rutgers, The State University of New Jersey:

Primary Outcome Measures:
  • Tobacco use abstinence [ Time Frame: 26 week ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Time to first relapse [ Time Frame: varies ] [ Designated as safety issue: No ]
  • Duration of medication use [ Time Frame: 26 weeks ] [ Designated as safety issue: No ]
  • Adverse clinical events [ Time Frame: 26 weeks ] [ Designated as safety issue: Yes ]

Enrollment: 127
Study Start Date: September 2005
Study Completion Date: January 2008
Primary Completion Date: December 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Nicotine patch, nicotine inhaler, bupropion
Drug: Nicotine patch, nicotine inhaler, bupropion
Patch - 21 mg - taper as able Inhaler - as needed Bupropion SR 150 mg daily
Active Comparator: 2
Nicotine patch
Drug: Nicotine patch
21 mg daily for 6 weeks followed by 14 mg for 2 weeks and then 7 mg for 2 weeks

Detailed Description:

Subjects randomly received either nicotine patch alone for a 10-week, tapering course (n=64) or the combination of nicotine patch, nicotine oral inhaler, and bupropion for an ad-lib duration (n=63).

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • currently smoking at least 10 cigarettes per day (confirmed by high exhaled carbon-monoxide (CO))
  • 18 years or older
  • interested in quitting within the next 30 days
  • one or more pre-defined medical illnesses (including cardiovascular disease, other vascular disease, chronic pulmonary disease, cancer, hypertension, diabetes, hyperlipidemia, and recurrent pulmonary infections)

Exclusion Criteria:

  • contraindications to pharmacotherapy (including unstable angina, myocardial infarction within 2 months, severe arrhythmia, seizure disorder, serious mental illness requiring antipsychotic medications)
  • current use of other tobacco products (smokeless tobacco, cigars, pipes, etc.), bupropion, clonidine, nortriptyline, or nicotine replacement medications
  • unable to give consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00770666

Locations
United States, New Jersey
Umdnj-Rwjms
New Brunswick, New Jersey, United States, 08903
Sponsors and Collaborators
University of Medicine and Dentistry of New Jersey
Rutgers Cancer Institute of New Jersey
Robert Wood Johnson Foundation
Investigators
Principal Investigator: Michael B Steinberg, MD, MPH UMDNJ-RWJMS
  More Information

No publications provided by Rutgers, The State University of New Jersey

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Michael Steinberg, MD, MPH, UMDNJ-Robert Wood Johnson Medical School
ClinicalTrials.gov Identifier: NCT00770666     History of Changes
Other Study ID Numbers: 0220055373
Study First Received: October 9, 2008
Last Updated: October 9, 2008
Health Authority: United States: Institutional Review Board

Keywords provided by Rutgers, The State University of New Jersey:
Tobacco dependence treatment

Additional relevant MeSH terms:
Bupropion
Nicotine
Antidepressive Agents
Antidepressive Agents, Second-Generation
Autonomic Agents
Central Nervous System Agents
Cholinergic Agents
Cholinergic Agonists
Dopamine Agents
Dopamine Uptake Inhibitors
Ganglionic Stimulants
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Nicotinic Agonists
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Therapeutic Uses

ClinicalTrials.gov processed this record on October 23, 2014